The EPS decline likely left investors hesitant, as Sino Biopharmaceutical's performance, with a 34% loss including dividends, underperformed the broader market's 16% loss. This may signal unresolved challenges, given it's worse than the 6% annualised loss over the last half decade.
Sino Biopharmaceutical Limited's high P/S ratio may not be justified due to its slower revenue growth. Investors may hope for a business turnaround, but analysts lack confidence. The weak revenue outlook could risk the share price and shareholder investments.
Company's declining EPS, below market expectations, may have deterred investors. Past performance led to total loss for shareholders, raising future concerns. Dividend payouts, assumed reinvested, helped offset some losses.
Key points: 1. Hang Seng Index fell 2.57% in the first two weeks (2023/05/22 to 2023/06/02), with all 12 Hang Seng industries falling. Among them, the Hang Seng healthcare sector fell 1.51%, outperforming the Hang Seng Index by 1.06 percentage points, ranking third among the 12 Hang Seng industries 2. On May 22, the results of the f...
HK Tech and Internet Stocks HK Tech and Internet Stocks
Stocks of companies primarily involved in technology and internet sectors in the HK stock market.Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in HK Tech and Internet Stocks, ranked from highest to lowest based on real-time market data. Stocks of companies primarily involved in technology and internet sectors in the HK stock market.Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in HK Tech and Internet Stocks, ranked from highest to lowest based on real-time market data.
Stirling : very strong support.
Samleecomp OP : Strong buy volume in recent move. Potentially Uptrend can continue